July 21, 2026

@michaelokun

Can replacing lost dopamine cells finally move us toward restoring the Parkinson’s brain? Dopaminergic progenitor cells are immature cells designed to develop into dopamine-producing neurons after transplantation. Paul, Barker and colleagues describe in a new paper in Nature Medicine the first 12-month results of the STEM-PD phase 1/2 trial evaluating human embryonic stem cell-derived dopamine progenitor cells for Parkinson’s disease. Key points: - The off-the-shelf stem cell product was successfully transplanted into the brains of eight folks w/ Parkinson’s disease and there were no serious safety events attributed to the transplanted cells, no tumors and no graft-induced dyskinesias during the first year. - Brain imaging suggested survival of transplanted dopamine-producing cells in several participants, especially in the higher dose group, providing encouraging biological evidence that the cells may be functioning. - Most participants were able to reduce their Parkinson’s medications during follow-up, however this was an early safety study and much longer follow-up is needed before drawing conclusions about clinical benefit. - The immunosuppression in one case was associated w/ pulmonary aspergillosis and death of one subject. My take: This paper represents another important milestone for regenerative medicine in Parkinson’s disease. We are now seeing reproducible evidence across multiple independent programs that transplanted dopamine cells can survive in the human brain. At the same time, this study reminds us to remain cautious. One participant died from complications related to the immunosuppression required for this allogeneic off-the-shelf product, emphasizing that the cells themselves may not be the greatest challenge, but rather how we safely support them after transplantation. The future may belong to approaches that combine durable cell replacement w/ safer immune strategies, or perhaps autologous approaches using a person's own cells that may eventually reduce or eliminate the need for immunosuppression. The future will also belong to approaches that will move us beyond the motor symptoms of Parkinson's.